Get the Stockscreener App
20.28
2.27%
-0.47
After Hours:
20.21
-0.07
-0.35%
Dyne Therapeutics Inc stock is traded at $20.28, with a volume of 2.57M.
It is down -2.27% in the last 24 hours and down -2.97% over the past month.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
See More
Previous Close:
$20.75
Open:
$20.68
24h Volume:
2.57M
Relative Volume:
0.99
Market Cap:
$2.90B
Revenue:
-
Net Income/Loss:
$-412.89M
P/E Ratio:
-5.2539
EPS:
-3.86
Net Cash Flow:
$-361.93M
1W Performance:
-7.40%
1M Performance:
-2.97%
6M Performance:
+44.96%
1Y Performance:
-26.89%
1-Day Range:
$20.14
$21.00
1-Week Range:
$19.45
$21.58
52-Week Range:
$6.36
$29.71
Dyne Therapeutics Inc Stock (DYN) Company Profile
Name
Dyne Therapeutics Inc
Sector
Industry
Phone
(781) 786-8230
Address
1560 TRAPELO ROAD, WALTHAM
Compare DYN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
20.28 | 2.95B | 0 | -412.89M | -361.93M | -3.86 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-25-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-24-25 | Initiated | Bernstein | Mkt Perform |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-29-25 | Initiated | Evercore ISI | Outperform |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-21-24 | Reiterated | Chardan Capital Markets | Buy |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | H.C. Wainwright | Buy |
| Feb-27-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Feb-15-23 | Initiated | Oppenheimer | Outperform |
| Jan-26-23 | Initiated | Guggenheim | Buy |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Outperform |
| Oct-12-20 | Initiated | JP Morgan | Overweight |
| Oct-12-20 | Initiated | Jefferies | Buy |
| Oct-12-20 | Initiated | Piper Sandler | Overweight |
| Oct-12-20 | Initiated | Stifel | Buy |
View All
Dyne Therapeutics Inc Stock (DYN) Latest News
Saturn V Capital Management LP Purchases Shares of 1,455,429 Dyne Therapeutics, Inc. $DYN - MarketBeat
Will Dyne Therapeutics Inc. stock benefit from automationStock Surge & Risk Adjusted Buy/Sell Alerts - Newser
Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? - AOL.com
JPMorgan Chase & Co. Has $29.39 Million Stock Holdings in Dyne Therapeutics, Inc. $DYN - MarketBeat
DYN: DMD and DM1 therapies near launch, with strong data and rapid commercialization plans - TradingView
Geode Capital Management LLC Has $21.46 Million Stock Position in Dyne Therapeutics, Inc. $DYN - MarketBeat
Franklin Resources Inc. Cuts Stock Holdings in Dyne Therapeutics, Inc. $DYN - MarketBeat
Bernstein Sees Favorable Risk-Reward for Dyne Therapeutics (DYN) Ahead of Major DYN-251 Data Release - Finviz
12 Best Upside Stocks to Buy Now - Insider Monkey
Ensign Peak Advisors Inc Has $2.53 Million Position in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne (DYN) Jumps 41% as Jefferies Bets Firm to Benefit from Novartis-Avidity Merger - MSN
Dyne Therapeutics Stock Soars After Rival Avidity Biosciences Gets Acquired By Novartis - MSN
Bernstein raises Dyne Therapeutics stock price target to $21 on favorable risk-reward - Investing.com Canada
Why Dyne Therapeutics Stock Was Crushing it This Week - The Globe and Mail
Will Dyne Therapeutics Inc. stock see PE expansionMarket Sentiment Summary & Verified Technical Trade Signals - newser.com
Why Dyne Therapeutics Inc. stock is favored by top institutions - newser.com
Can Dyne Therapeutics Inc. stock reach $100 price targetWall Street Watch & Low Drawdown Investment Ideas - newser.com
Is Dyne Therapeutics Inc. stock attractive for long term wealth buildingWeekly Trading Summary & AI Optimized Trade Strategies - newser.com
Dyne Therapeutics Inc.’s volatility index tracking explained2025 Price Momentum & Low Risk Entry Point Guides - newser.com
Will Dyne Therapeutics Inc. stock deliver better than expected guidanceQuarterly Market Summary & Weekly Stock Breakout Alerts - newser.com
Will Dyne Therapeutics Inc. stock go up soon2025 Market Sentiment & Verified Technical Trade Signals - newser.com
Is Dyne Therapeutics Inc. reversing from oversold territoryIPO Watch & Reliable Breakout Forecasts - newser.com
Historical volatility pattern of Dyne Therapeutics Inc. visualized2025 Major Catalysts & Capital Protection Trading Alerts - newser.com
Dyne Therapeutics Inc. stock volume spike explainedInflation Watch & High Return Trade Guides - newser.com
Technical Reactions to DYN Trends in Macro Strategies - news.stocktradersdaily.com
Dyne Therapeutics (NASDAQ:DYN) Price Target Cut to $17.00 by Analysts at JPMorgan Chase & Co. - MarketBeat
Technical analysis overview for Dyne Therapeutics Inc. stock2025 Macro Impact & Low Drawdown Momentum Ideas - newser.com
Why Dyne Therapeutics Inc. stock is seen as undervalued2025 Major Catalysts & Weekly Chart Analysis and Trade Guides - newser.com
Dyne Therapeutics Inc Stock (DYN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.44%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):